David joined Pivotal Life Sciences in 2018. Prior to joining Pivotal he was the Chief Business Officer at BioLineRx (NASDAQ: BLRX), a drug development company, where he established partnerships with Novartis, Roche/Genentech and Merck and was involved in raising over $100 million. Prior to that David held a variety of leadership roles at Sanofi (NASDAQ: SNY), mainly in corporate and business development functions. David serves on the board of directors of Avalyn Pharma, aptihealth and Encodia. David earned his MBA at the Tuck School of Business at Dartmouth, and his B.A. in Statistics from the University of Haifa.
Venture Partner – Pivotal bioVenture Partners (US)